ESTROGEN BLOCKERS MARKET ANALYSIS

Market News

Recent Developments

Marketed Products

• Fulvestrant (Faslodex). Fulvestrant is a third-generation aromatase inhibitor that is approved for the treatment of advanced breast cancer in women who have already received other hormonal therapies. It is also being investigated for the prevention of breast cancer in women who are at high risk.
• Ospemert (Jemperli). Ospemert is a monthly subcutaneous injection that is approved for the treatment of advanced breast cancer in women who have already received other hormonal therapies. It is a selective estrogen receptor degrader (SERD), which means that it works by binding to and degrading the estrogen receptor.
• Trametinib (Mekinist). Trametinib is a kinase inhibitor that is approved for the treatment of advanced breast cancer in women who have a BRAF V600E mutation. It works by blocking the activity of the BRAF protein, which is involved in the growth of cancer cells.

Product Launch and Approval  

• On June 5, 2023, Pfizer Inc., a pharmaceutical company, announced that DUAVEE (conjugated estrogens/bazedoxifene), an estrogen-based menopause hormone therapy, was reissued in stock in the U.S., with improved packaging following a voluntary recall in May 2020. The recall was due to an issue with the packaging and was not based on any efficacy or safety concerns with the product itself.
• On May 13, 2023, Astellas Pharma Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved VEOZAHTM (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. VEOZAH is the first nonhormonal neurokinin 3 (NK3) receptor antagonist approved to treat VMS due to menopause.
• In October 2021, the U.S. Food and Drug Administration (FDA) announced the approval of Eli Lilly and Company\'s, a pharmaceutical company, Verzenio (abemaciclib), in combination with endocrine therapy (tamoxifen or an aromatase inhibitor), for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at high risk of recurrence and a Ki-67 score of ≥20% as determined by an FDA-approved test. Ki-67 is a marker of cellular proliferation. Verzenio is the first and only CDK4/6 inhibitor approved for this patient population.

Research & Development, Collaboration and

• In October 2022, AstraZeneca, a global pharmaceutical company, announced the positive results from the CAPItello-291 Phase III trial, with an aim to study capivasertib in combination with Faslodex (fulvestrant) that demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus placebo plus Faslodex in patients with hormone receptor (HR)-positive, human epidermal growth fact